Aim 1. To determine the feasibility and effectiveness of IVR (interactive voice response)-administered EPIC

Aim 2. To determine the effectiveness of providing individually tailored versions of Michigan Cancer Consortium (MCC) guidelines for post-treatment care to patients and their primary care providers.

Aim 3. To measure PCP acceptance and implementation of the MCC guidelines.

Approximately 150 prostate cancer patients within 1 year of surgery or radiation therapy at UM

Study 1: Mode Effect: Patients are recruited at their 3-month post-prostatectomy urological visit where they complete a paper version of EPIC. Three days later, patients complete an IVR_administered version of EPIC. Results are compared to determine a mode effect.

Study 2: Intervention: Patients are recruited at their 3-month post-prostatectomy urological visit. In week 1, patients are administered EPIC via IVR. Based upon the patients' responses, patients and their primary care providers receive tailored versions of Michigan Cancer Consortium (MCC) guidelines for treatment and self-management of post-surgery side effects. Patient newsletters include sections explaining their symptoms, what to expect, self management of symptoms, medical treatment options, how to talk to their doctor and testimonials. PCP letters include a summary of the patient newsletter along with MCC guidelines for treatment of the patient's symptoms. Patients receive a call again in week 3 to rate helpfulness of the newsletter, measure change in efficacy to self manage and understanding of symptoms. In week 5, EPIC is re-administered.